Aşkın Gülşen1. 1. Interdisciplinary Allergy Outpatient Clinic, Department of Pneumology, University of Lübeck, Germany.
Abstract
OBJECTIVES: The aim of our study was to examine pulmonary functions of patients from all stages of chronic obstructive pulmonary disease (COPD) according to their smoking status. MATERIALS AND METHODS: A retrospective case-control study was carried out. Total of 148 patients were enrolled and divided into two groups in regards to their smoking status (quitters, n=68; non-quitters, n=80). Pulmonary function parameters, COPD assessment test score, Fagerström Nicotine Addiction Questionnaire score, smoking history and status were obtained from the electronic hospital data system. Patients' admission and 12-month data were recorded. RESULTS: In non-quitters, the mean FEV1 values decreased from 2.32±1.14 to 2.24±1.12 (p<0.001). Particularly, in Stage-0, in the early high-risk group of COPD, the reduction in FEV1 was 90 mL, while the reduction was 70, 60, 40, and 40 mL in Stage-I, -II, -III, and -IV, respectively. In quitters, the mean FEV1 levels increased from 2.10±1.19 to 2.19±1.20 (p<0.001). For COPD patients overall, an average increase in FEV1 of 80-110 mL was observed. At the end of the 12 months follow-up, 17 (27.5%) of the non-quitters showed deterioration, and five (7.3%) of the quitters showed improvement in COPD stage. CONCLUSION: FEV1 decline was accelerated in COPD patients who continued to smoke, whereas this decline was not prevented by inhaler treatments. The Global Initiative for Chronic Obstructive Lung Disease Stage-0 group, which is not included in the current guidelines, needs to be redefined. This group appears to be the most important group for implementing the smoking cessation and prevention strategy.
OBJECTIVES: The aim of our study was to examine pulmonary functions of patients from all stages of chronic obstructive pulmonary disease (COPD) according to their smoking status. MATERIALS AND METHODS: A retrospective case-control study was carried out. Total of 148 patients were enrolled and divided into two groups in regards to their smoking status (quitters, n=68; non-quitters, n=80). Pulmonary function parameters, COPD assessment test score, Fagerström Nicotine Addiction Questionnaire score, smoking history and status were obtained from the electronic hospital data system. Patients' admission and 12-month data were recorded. RESULTS: In non-quitters, the mean FEV1 values decreased from 2.32±1.14 to 2.24±1.12 (p<0.001). Particularly, in Stage-0, in the early high-risk group of COPD, the reduction in FEV1 was 90 mL, while the reduction was 70, 60, 40, and 40 mL in Stage-I, -II, -III, and -IV, respectively. In quitters, the mean FEV1 levels increased from 2.10±1.19 to 2.19±1.20 (p<0.001). For COPDpatients overall, an average increase in FEV1 of 80-110 mL was observed. At the end of the 12 months follow-up, 17 (27.5%) of the non-quitters showed deterioration, and five (7.3%) of the quitters showed improvement in COPD stage. CONCLUSION: FEV1 decline was accelerated in COPDpatients who continued to smoke, whereas this decline was not prevented by inhaler treatments. The Global Initiative for Chronic Obstructive Lung Disease Stage-0 group, which is not included in the current guidelines, needs to be redefined. This group appears to be the most important group for implementing the smoking cessation and prevention strategy.
Authors: Jaideep Dhariwal; Rachel C Tennant; David M Hansell; John Westwick; Christoph Walker; Simon P Ward; Neil Pride; Peter J Barnes; Onn Min Kon; Trevor T Hansel Journal: Chest Date: 2014-05 Impact factor: 9.410
Authors: Surya P Bhatt; Julie A Anderson; Robert D Brook; Peter M A Calverley; Bartolome R Celli; Nicholas J Cowans; Courtney Crim; Fernando J Martinez; David E Newby; Jørgen Vestbo; Julie C Yates; Mark T Dransfield Journal: Eur Respir J Date: 2018-01-18 Impact factor: 16.671
Authors: Claus F Vogelmeier; Gerard J Criner; Fernando J Martínez; Antonio Anzueto; Peter J Barnes; Jean Bourbeau; Bartolome R Celli; Rongchang Chen; Marc Decramer; Leonardo M Fabbri; Peter Frith; David M G Halpin; M Victorina López Varela; Masaharu Nishimura; Nicolás Roche; Roberto Rodríguez-Roisin; Don D Sin; Dave Singh; Robert Stockley; Jørgen Vestbo; Jadwiga A Wedzicha; Alvar Agustí Journal: Arch Bronconeumol Date: 2017-03-06 Impact factor: 4.872